Method for generating large quantities of mast cells for use in allergy drug research


An improved method for robust and rapid production of large quantities of homogeneous mast cells suitable for research, drug discovery and cell therapy to treat allergy, anaphylaxis and autoimmune disorders.

mucosal and connected tissue type mast cells

APPLICATION

Drug discovery & screening (allergy, anaphylaxis and autoimmune disorders)

DEVELOPMENT STATUS

Early stage laboratory data / Proof of concept

IP STATUS

UK priority application filed June 2016.

COMMERCIAL OFFERING

Licensing and/or collaborative research.

OPPORTUNITY


The global market for antihistamine and nasal allergy drugs is worth $7.6 billion, with 95 million seasonal allergy sufferers in USEU and Japan. In the development of drugs against allergy, mast cells are a key target cell type and are used to see if a given compound prevents degranulation and release of histamine. Many companies want to access or provide mast cells commercially, but existing culture methods for generating mast cells are lengthy, inefficient and do not generate large numbers of pure mast cells.

TECHNOLOGY


Mast cells are key player in the inflammatory response and are implicated in allergy, anaphylaxis and autoimmune disorders. This technology is a useful improvement on current techniques, which makes use of a 3-step methodology: bioengineering of pluripotent stem cells with a key reporter construct; cellular expansion; and Fluorescence-activated cell sorting (FACS) enrichment, which generates a rapid, high yield of pure and highly proliferating immature and mature mast cells.

At present there is proof-of-concept data from mouse embryonic stem cells that have undergone a ~50-fold expansion within 21 days. All of the cells demonstrate the morphological characteristics of mast cells and expressed typical mast cell mediators following stimulation. Additionally, there is some preliminary data from human induced pluripotent stem cells which is currently in development.

BENEFITS


  • Potential for high cost savings
  • Provides a robust functional cell population for studies
  • Saves on user time, reduced culture times, less variability
  • Applicable to embryonic and induced pluripotent stem cells

Please note, the featured image is purely illustrative.

Source: iStock

Enquire about Method for generating large quantities of mast cells for use in allergy drug research

11 + 8 =